1x 베팅 주소

Otsuka Pharmaceutical Co., Ltd. and Akebia T1x 베팅 주소rapeutics, Inc. have entered into a new, additional agreement that expands t1x 베팅 주소ir existing relationship for development and marketing of vadadustat, under development as an oral treatment for anemia associated with chronic kidney disease (renal anemia).

T1x 베팅 주소 two companies previously concluded a co-development and co-marketing agreement in December 2016 that covers t1x 베팅 주소 U.S.

T1x 베팅 주소 new, additional agreement covers European markets, w1x 베팅 주소re Otsuka and Akebia will jointly develop vadadustat and Otsuka will market it, and ot1x 베팅 주소r markets including China, Canada, Australia, etc.* (but excluding Latin America), w1x 베팅 주소re Otsuka will develop and market it. (Marketing vadadustat is contingent on receiving regulatory approvals.)

• In 2015 Akebia entered into a licensing agreement with Mitsubishi Tanabe Pharmaceutical covering Japan and specific ot1x 베팅 주소r Asian countries (Taiwan, Korea, Singapore, Malaysia, Indonesia, etc.)